Are All Calories the Same? – SELF

There's a lot of confusing messaging when it comes to health, nutrition, and weight loss . Imagine my surprise when I read that several foods listed under the headline 30 Foods Never to Eat After Age 30 were also in a story called 10 Foods to Boost Libido. As a thirtysomething woman, I really wondered if the wellness industry was trying to tell me something.

(Whatever it is, you can tell it to my medicine cabinet full of antiaging skin-care products and my armoire of sex toys . Yes, I have a literal armoire. Who needs a list of libido boosters anyway?)

With all the conflicting information floating around the Internet, its no wonder we have so much confusion about what we should eat, how much of it, and how to stay healthyand why we're convinced that some foods are good, some are bad, and some you absolutely shouldnt eat.

The easy answer is that you shouldnt eat raw chicken , anything that you have a diagnosed allergy to, and any overpriced magical brew claiming it will detox you . Other than that, if you want to know how and what to eat for health, you can learn about the basics and figure out from there what works for you.

In the scientific sense, a calorie is the unit of energy needed to raise 1 gram of water 1 degree Celsius. When you think of calories, think of them like that: as energy. The stuff that keeps you going. Dont overfill your tank and flood the engine, but youre going to have a lot of problems trying to run on empty.

Calories come from three main macronutrients: protein, carbohydrates, and fats. Everything you eat is some combination of macronutrients (except maybe mushroomsand whatever Gwyneth Paltrow lives on). They all have uses in the body in appropriate amounts, even cholesterol , which is a type of fat, and sugar, which is a carbohydrate. Each macronutrient can be used as an energy source, and technically each produces the same unit of energy per calorie. That being said

The macronutrients all have very different chemical structures and complex sets of jobs in your body. Let's take a look at each one.

At 4 calories per gram, we generally think of carbohydrates mainly as a source of energy, and thats pretty accurate. Theyve gotten a bad rep in the last few decades or so, but your brain lives on sugar . Remember eating Cocoa Pebbles before big exams? Fine, maybe that was just me, but it actually was based on sound science. If youre active, carbs are a great source of energy. The "problem" with carbs, which isn't actually a problem, but rather just a question of math, is that when you're not active, or you eat way more simple carbohydrates than your body can use for energy, it gets stored as fat. And the truth is, yeah, a lot of us eat a lot more carbs than our bodies need.

You also may have read recently that sugar is as addictive as cocaine, which sounds bad, but actually isn't the case. While the lure of sugar can be strong for some people, current science just doesnt seem to support that headline-friendly notion. Really, when was the last time someone sold their possessions for a cronut? A 2014 study from the University of Edinburgh found that people could show addiction-type patterns around eating, but that sugar and fat themselves did not promote addictive behavior. So enjoy carbohydrates in the right amount for your activity level.

Fat has multiple uses in the body. Its used in cell wall repair, hormone regulation, and storage of fat-soluble vitamins. An extreme lowfat diet can impede any one of these. The reason why fat gets a bad reputation is that it packs 9 calories per gram, and a lot of high-fat foods are not extremely nutrient-dense. You dont need to be scared of bacon (because bacon), but moderation is key when it comes to keeping your caloric intake from fatty foods in line with what your body needs for fuel.

And speaking of bacon, lets talk protein, that thing were never quite sure if were getting enough of but are strangely lured in by if we see the number of grams of it on a label. Protein is responsible for a lot of the little repairs your body needs done on a daily basis and, of course, building muscle. Like carbohydrates, protein has 4 calories per gram. But unlike carbs, a huge advantage of protein is that its the best macronutrient for satiety, according to a meta-analysis from a 2016 study from Purdue University. A lot of people worry about getting enough protein , but all reports show that youre getting plenty of it just by eating a varied diet. Dont be dragged in by the labels that say added protein unless youre trying to grow biceps on your biceps.

Yes , but your body can also convert protein and fat into sugar. When needed, there are pathways for each calorie source to be converted to a usable form of fuel. Conversely, every calorie source can be converted and stored as fat if you have an excess of calories in your system. Busting a related myth, you do not convert fat into muscle when you lose weight. You can lose fat and gain muscle simultaneously giving the impression that this happens, but fat deposits cannot be converted directly into muscles.

It really depends on your caloric needs, but in general terms foods that we consider healthy tend to have a high ratio of micronutrients (i.e., vitamins and minerals) per calorie. Vegetables, lean meats, fruits, berries, whole grains, and lentils are all examples of foods that easily meet this criteria.

Theres no morality with food or calories. The food simply is, and its up to you to make intelligent choices with the food and your health and once in a while, with your taste buds, because godammit, cronuts exist. Moderation, but get the veggies first!

A lot of that comes down to personal preference. Nobody is great at tracking calories not even registered dietitians because we all tend to incorrectly estimate our intake. So how do we manage this? Find what works for you. Long term, theres no advantage to a low-carb diet versus a lowfat diet for weight loss, because both work the same way: by inducing a caloric deficit. For every story like Supersize Me , theres a guy who loses 56 pounds eating nothing but McDonald's while meticulously counting calories. Every diet plan will work if you stick to it because, no matter what, diets work by inducing a caloric deficit. Truly, the best diet plan is one that you can stick to. (Not that sticking to a diet is an easy featit isn't, and dieting can be a complicated journey. But that's another story.)

Fruits and vegetables are mainly carbohydrate, fiber, and water. Lentils are protein and carbs. Meats are protein and fat. And processed foods, well, read the labels and find out. But theres nothing intrinsically wrong with any of them, not even candy. Theyre all just combinations of calories. If you want to enjoy something thats a dense source of calories, enjoy it. If youre trying to lose or maintain your weight, just keep track of it. And never let an online list tell you that there are caloriesor anythingthat youre too old to enjoy.

Yvette d'Entremont holds a B.S. in chemistry,B.A. in theatre,and a master's degreein forensic science with a concentration in biological criminalistics. She worked for eight years asananalytical chemist before her blog focused on debunking bad science, scibabe.com , turned into a full-time job in science communications. Follow her on Twitter and Facebook .

You might also l
ike: 5 Signs You're Not Eating Enough Calories

Continue reading here:
Are All Calories the Same? - SELF

MEL Science Launches Virtual Reality Chemistry Lessons – T.H.E. Journal

STEM and VR

MEL Science, based in London, has launched a series of virtual reality (VR) chemistry lessons for K12. The 3-year-old company this week released a MEL Chemistry VR app, featuring a virtual chemistry lab, for free on Google Daydream. This free version, which contains the first six chemistry lessons, is available at this MEL Science site.

According to MEL Science, chemistry is filled with abstract concepts that may prove difficult for young students to understand. The best method for kids to learn is through hands-on interaction, so MEL Science developed these VR chemistry lessons to enliven molecular-level science and illustrate it on an immersive, enlarged level.

The lessons follow K12 curricular guidelines, and are designed to be used in the classroom or at home. A special version for educators will be released soon, the company said.

In these first six lessons, students should be able to see what its like to dive into a pencil (graphite) or a diamond and discover what these objects look like on an atomic level.

Students should be able to learn about basic chemistry principles in an interactive, friendly way, including topics such as:

Students will also get the opportunity to build an atom of any known element with their hands and/or a guiding tool. Anything that appears on the modern periodic table should be available to build, said Vassili Philippov, CEO of MEL Science.

MEL Science aims to release more than 150 lessons covering all the main topics included in K12 schools chemistry curriculum. Later this year, MEL Science also aims to add support for other VR platforms, including Google Cardboard and Samsung Gear VR.

MEL Science is known for its subscription service, offering educational science sets through the mail. Through this service, parent subscribers get two new chemistry sets every month, allowing them to perform engaging educational experiments at home with their children.

Wed like to change science education, Philippov said in an interview. Virtual reality is the perfect language for science, because you can see what is happening on the micro level. You cant see molecules. But with virtual reality, you can be inside a chemical reaction. You can memorize facts and forget later, or I can put you inside a chemical reaction. Then youll really understand what is happening there. So fundamentally, its a better way to teach science.

Philippov continued, If you understand how to motivate kids, youll really teach them. In science, there is one trick hands-on experience. They have to see it with their eyes. Then theyll really fall in love, and youll inspire their natural curiosities. If you combine those two together engagement and using VR theyll understand what is happening on a fundamental level. Thats the way to teach science.

To witness the MEL Chemistry VR app in action, view the video below:

More information on MEL Chemistry VR can be found at the companys site.

About the Author

Richard Chang is associate editor of THE Journal. He can be reached at rchang@1105media.com.

Here is the original post:
MEL Science Launches Virtual Reality Chemistry Lessons - T.H.E. Journal

This Biotechnology Company Wants to Reanimate the Brain-Dead – TrendinTech

Ira Pastor, CEO of Bioquark, a Philadelphia-based biotechnology company, believes we will on day be able to reset the brain of patients declared brain-dead using a series of stem cell injections and nerve stimulations.

Until recently, death was medically defined as a loss of heart and lung function but as medical technology has advanced so has the qualifications. Now, since both heartbeat and breathing functions can be performed for a patient by machine, death is almost universally declared when there is a loss of activity in the brain stem. However, Pastor does think that this loss of brain function is as irreversible as weve come expect.

Initially, Bioquark was slated to start trials for the procedure last year in India but, due to strong opposition by the Indian Council of Medical Research, those studies were canceled. Nevertheless, Ira Pastor and his collaborator Himanshu Bansal, an orthopedic surgeon, remain undaunted and have announced a new series of test to happen soon in a nameless South American country.

Although they have not released the details of the revolutionary procedure, we can gather a general idea of their plan to reanimate the brain-dead from the papers regarding their original canceled trial.

Originally, the researchers wanted brain-dead subjects between the ages of 12 and 65. Ideally, the cause of the brain damage would be due to traumatic injury. Scientists would look at MRIs to determine eligibility, then brain cells would be harvested from the patients blood. After the stem cells are injected, the patients would get another injection, this time peptides, directly to the spinal column. The series of injections is followed by two weeks of nerve stimulation, specifically the median nerve, by lasers, which Bioquark thinks is the key to reversing brain death.

Bioquark has not clarified how it intends to obtain consent from technically dead patients but in spite of the controversy, this study is not alone. The work at Bioquark is part of a larger program concerning neuro-reanimation and regeneration called ReAnima.

Pastor, who also serves on the advisory board for the project, told the Daily Mail: The mission of the ReAnima Project is to focus on clinical research in the state of brain death, or irreversible coma, in subjects who have recently met the Uniform Determination of Death Act criteria, but who are still on cardio-pulmonary or trophic support a classification in many countries around the world known as a living cadaver.

More News to Read

comments

Read more from the original source:
This Biotechnology Company Wants to Reanimate the Brain-Dead - TrendinTech

Biochemistry & Biophysics – University of Rochester Medical …

URMC / Biochemistry & Biophysics

The Department of Biochemistry & Biophysics (B&B) strives to understand the molecular mechanisms of important biological processes, thereby providing insight into how disruption of these mechanisms causes disease. Departmental research is generously supported by the National Institutes of Health (NIH). NIH instrument funds have contributed to our recent two million dollar investment in cutting edge structural biology, biophysical and mass spectrometry-based equipment. Furthermore, income generated from intellectual property derived from departmental research discoveries continues to be reinvested back into the department, and used to stimulate the genesis of private biotechnology companies.

In addition to supporting our research, the NIH has recognized our excellence in the Biochemistry & Molecular Biology (BMB) and Biophysics, Structural & Computational Biology (BSCB) Ph.D. programs by awarding the university a highly competitive interdepartmental T32 graduate training grant. Our commitment to graduate education is apparent from the positions acquired by our previous students and fellows, who are professors at major research universities and leaders in corporate research. Our continued focus on pioneering research and quality education ensures our position as a premier Biochemistry & Biophysics department.

Jeffrey J. Hayes , Ph.D. Chair, Department of Biochemistry & Biophysics

Unraveling the Role of RNA Structure in Gene Regulation Through Studies of the RNA Helicase Dbp2/DDX5

Elizabeth J. Tran, Ph.D. Associate Professor, Department of Biochemistry, Purdue University, West Lafayette, IN

Wed, Sep 27 - 2:00 PM MC K-307 (3-6408)

All Seminars

May 26, 2017 Study: A New Way to Slow Cancer Cell Growth

April 27, 2017 Using rooster testes to learn how the body fights viruses

April 1, 2017 BMB, BSCB Students Win 2017 Edward Peck Curtis Award for Excellence in Teaching by a Graduate Student

February 7, 2017 Maquat Receives Lifetime Achievement Award in Science from International RNA Society

December 12, 2016 Mitchell O'Connell Lab To Open

All news

Visit link:
Biochemistry & Biophysics - University of Rochester Medical ...

Respected Internist, E. Martin Maida, MD, is to be Recognized as a 2017 Top Doctor in Livingston, New Jersey – PR NewsChannel (press release)

E. Martin Maida, MD, an MDVIP-affiliated internist in Livingston, has been named a Top Doctor in Livingston, New Jersey. Dr. Maida is an attending physician at RWJ Barnabas Health Center. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care.

Dr. E. Martin Maida is a highly experienced internist, having been in practice for nearly three decades. His long and successful medical career began in 1985, when he graduated from the School of Medicine and Surgery at the University of Torino, Italy. He completed an internship, residency and served as chief resident at Saint Barnabas Medical Center, where he has attending privileges

With his wealth of experience as an internist to call upon, Dr. Maida diagnosis and treats a wide range of conditions for patients ages 18 to 100+. He is certified in bariatric medicine, helping patients lose weight and improve their overall health. He is also certified in the Bale Doneen method of cardiovascular prevention as well as anti-aging medicine including the use of bioidentical hormone replacement therapy. Dr. Maida also continues to practice what he advocates, as a long time practitioner of the martial arts (7th degree black belt), that exercise is crucial to overall well being.

As an MDVIP physician, Dr. Maidas practice focuses on wellness and prevention and is noted for its patient centric approach, finding tailored solutions for each individual patient. As the Director of the Livingston location of the Center for Medical Weight Loss, he offers medically supervised weight loss programs as an adjunct in the goal to maintain health and wellness for his patients. Just recently, Dr. Maida became certified in the technique of CoolSculpting, an FDA approved fat loss technique that requires no down time.

About Top Doctor Awards

Top Doctor Awards specializes in recognizing and commemorating the achievements of todays most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.

See the rest here:
Respected Internist, E. Martin Maida, MD, is to be Recognized as a 2017 Top Doctor in Livingston, New Jersey - PR NewsChannel (press release)

Fennel Reduces Postmenopause Symptoms – Anti Aging News

Posted on June 13, 2017, 6 a.m. in Women's Health Botanical Agents Sleep

Study confirms the benefits of fennel in reducing postmenopause symptoms such as sleeplessness, hot flashses, vaginal dryness, and anxiety.

A recent study has confirmed that fennel helps minimize postmenopause symptoms. This herbal medicine is rapidly growing in popularity as it has helpedcountless women across the globe manage their postmenopause symptoms. Women love the fact that fennel doesnot have any serious side effects.

About Fennel

Fennel is an herb commonly used in cooking. It has an anise flavor that is quite pleasing to the palate. The herb has long been valued for providing an array of health benefits for all sorts of issues ranging from digestion problems to premenstrual symptoms. Fennel has essential oils and phytoestrogenic properties. Similar to estrogen-like chemicals found in plants, phytoestrogens are used to successfully treat myriad menopause symptoms.

The New Study

The study referenced above confirms fennel is quite effective in managing postmenopause symptoms like anxiety, sleeplessness, hot flashes, irritability, depression, joint discomfort and vaginal dryness. The study results were recently published in The North American Menopause Society (NAMS) online journal Menopause.

Women have made use of alternative and complementary medicine for menopause symptom management across the past decade-plus. There has been a steady movement away from hormone therapy (HT) as it has its fair share of side effects. Though HT is a highly effective means of treating the majority of menopause symptoms, women are turning to herbal medicine in droves. Some are not candidates for HT while others are fearful of the side effects.

The study was conducted in Tehran, Iran. Women who live in Tehran reach menopause at a younger age (48.2 years) than women who reside in the United States (51 years). Soft capsules with 100 mg of fennel were provided to Iranian women between the ages of 45 and 60. The capsules were consumed two times per day over an 8-week period. The study was comprised of 79 women, some of whom were in a placebo group.

The intervention and placebo groups were compared at the following intervals: four, eight and 10 weeks. A major statistical difference was noted. Fennel proved to be an effective and safe means of decreasing menopause symptoms without inducing major side effects. This is one of the first clinical studies to determine if the benefits of fennel for the management of menopause symptoms had merit. Fennel was previously studied to determine if it was effective in managing premenopause symptoms. It was determined that fennel helped in managing these symptoms.

The Findings

The study determined that consuming fennel two times per day alleviated the severity of menopause symptoms. The placebo had minimum effect. It is still necessary to conduct a longer and larger randomized study yet these findings make it clear that fennel is quite effective for reducing postmenopausal symptoms.

Read this article:
Fennel Reduces Postmenopause Symptoms - Anti Aging News

Inside Ambrosia: Could infusions of millennial blood make you young again? Scientists have doubts. – Mic

According to Greek mythology, when you consume ambrosia, the blood running through your veins is replaced with ichor, a golden fluid. Ambrosia, consumed only by gods and goddesses, grants immortality.

Ambrosia is also the name of a startup that aims to combat aging. Rather than golden fluid flowing through the veins of gods, the company's product is the blood of the young actual blood, donated by adults up to age 25 which it will inject in customers 35 and older who have $8,000 to spare.

The question remains: Do young blood injections actually work? Are we just a needle prick away from sweet, fresh-faced longevity?

"I know what you're thinking," said Ambrosia founder Jesse Karmazin in an interview. "Is it all just, like, Silicon Valley tech people?"

It's true: Silicon Valley has a fascination with immortality. Investors have poured billions into longevity research and startups. Venture capitalist Peter Thiel, the billionaire Facebook board member and adviser to Trump, has invested millions into anti-aging medicine. Ambrosia hasn't raised any capital yet, and Karmazin told me that the company has no affiliation with Thiel.

Actually, Karmazin said, Ambrosia's client base is "a real mix of different types of people."

Karmazin said that it's mostly Americans currently undergoing the treatment, with slightly more men than women. He said the company has treated doctors, lawyers, biotech CEOs, someone with a theater background and other individuals from a variety of different industries.

A quote from Jesse Karmazin

Ambrosia currently has two clinics, one in Florida and one in San Francisco. "The treatment is large: It's two liters, which is a pretty significant amount of blood. It's like four pints if you use the American measuring system."

Still, for $8,000 a pop, blood injections are meant for customers who tend to have a little more disposable income. Ambrosia may not be affordable for everyone, but the pricing is reportedly at cost for now; Ambrosia isn't making any money from it yet.

The company gets its spritely plasma from blood donors. It buys blood from blood banks, an industry Karmazin noted is both heavily regulated and expensive.

Karmazin said that the company has both subjective and objective evidence that its treatment is conclusive. He mentioned clients who looked younger after the treatment, as well as people having more energy, sleeping better and feeling stronger. He also noted that people have had "dramatic improvements in Alzheimer's disease."

From an objective standpoint, Karmazin said the Ambrosia treatment can improve cholesterol, amyloid levels plaques in the brain and cancer risk.

"I want to be clear, at this point, it works," Karmazin said. "It reverses aging. We're pretty clear at this point. This is conclusive. We are probably done with the clinical trial. It worked so well, we're going to start treating people. We're pretty amazed with this. Yeah, no, it works, there's really no question whether it works or not."

"I want to be clear, at this point, it works," Karmazin said. "It reverses aging. We're pretty clear at this point. This is conclusive. There's really no question."

But the lack of science casts doubt on Karmazin's confidence.

Evidence on the Ambrosia website includes a handful of links to both human clinical trials and mouse experimental studies. Of the six total human clinical trials included, one is sponsored by Ambrosia. The study was first received in June of 2016. The longest trial dates back to September 2014. The trials aren't yet completed. Some of then haven't even started enrolling yet. And they're small one has just 18 people. Phuoc V. Le, an assistant professor in the school of Public Health at University of California Berkeley and associate professor of Internal Medicine at UC San Francisco School of Medicine, said a clinical trial of this size is "minuscule" and just a first step to make sure there aren't any adverse reactions.

"Something like this needs to have large clinical trials for years before they can make claims as hefty as what they're making," Le told Mic. He added that "this is years and years away" and that that is something consumers need to be aware of. "This is an unproven remedy."

A quote from Phuoc V. Le

Nir Barzilai, a professor of endocrinology at Albert Einstein College of Medicine and the director of Einstein's Institute for Aging Research, also agreed that Ambrosia's treatment can't be called conclusive just yet.

There would have to be clinical trials where some elderly participants receive infusions of something else rather than the blood from younger people because the placebo effect in such trials is high, he said.

Derek Huffman, assistant professor of molecular pharmacology and medicine at the Albert Einstein College of Medicine, said in an email that the willingness to treat individuals with transfusions for aging at this point is, in his view, "a distortion of the studies it is based on, and an example of an idea getting too far ahead of the science." He added that "this is not to say that this burgeoning area of science is not promising, and that related strategies will not one day come to fruition to successfully target aging, but they will require a much more targeted and fine-tuned approach than is being suggested here.

Le noted that for vulnerable populations, such as people suffering from stroke or early-onset Alzheimer's or dementia, they can't and don't want to wait, so it's dangerous for Ambrosia to make promises of reversal or amelioration of their conditions that are inconclusive, and at a considerable cost.

"For example, if I had early-onset dementia and I lived in Palo Alto and I'm a retiree and I'm living off of social security but I saved up $8,000, and I've seen my parents die of dementia, and saw how bad it was, I might consider spending essentially my savings on something that is unproven," Le said. "Although they are selling it as, not a cure-all, but potentially life-altering and so I worry that it's clearly not coercion but I worry that that people will fall into this trap of spending big bucks and not getting approving benefits."

It's also important to consider the ethical implications of companies like Ambrosia. As Karmazin mentioned, the company gets it plasma by purchasing blood from blood banks. If this type of treatment were to scale up, and companies had millions of people using it, the demand for young blood would be astronomical.

"Could we see a day when young people are selling their blood on the open market for companies like Ambrosia?" Le hypothesized. "And then what do we do in terms of balancing the public good? Meaning, if I were a patient in a hospital and I required plasma because I have a really bad medical condition, but maybe the Red Cross can't get any, because people would rather sell their blood to a company than to donate their blood because it's a limited public good."

Le compared this commodification of blood to the organ black markets in developing countries, noting how this can disproportionately coerce and hurt the poor while benefiting the wealthy. Someone can donate their kidney to a rich person and, as he noted, the type of individual to do this is someone extremely impoverished.

If large clinical trials do bear out, great. But Le believes there could be more benefits yielded from that type of research than just an outpatient elective treatment like Ambrosia. He said that we should f
igure out what is in plasma that actually confers the benefits, and potentially try and isolate that.

Le said that perhaps medical experts can make plasma synthetically, from animals or in a way that doesn't commodify a public good like blood. That way, it "can provide benefit not just to the rich or to the extremely desperate but also make it available equally to all people."

Go here to read the rest:
Inside Ambrosia: Could infusions of millennial blood make you young again? Scientists have doubts. - Mic

A Top Dermatologist Weighs in on Miranda Kerr's Leech Facial – NewBeauty Magazine (blog)

Theres no better place to confess indulging in weird or off-the-wall beauty treatments than in the presence of Gwyneth Paltrow at the Goop Health Summit. Miranda Kerr did just that over the weekend when she sat on a star-studded panel of beauty and lifestyle expertsincluding Cameron Diaz, Nicole Richie, Tory Burch and Paltrow herselfand spoke about her experience with leech therapy.

You May Also Like:Why Is Gwyneth Paltrow Purposely Getting Stung By Bees for Beauty?

Ive had a leech facial, said Kerr. I kept the leeches, theyre in my koi pond. Youre not allowed to reuse them, and if you dont take them home, then she kills them, and I didnt like that idea. The model and KORA Organics beauty brand owner also admitted to using leech therapy on her tailbone.

Surprisingly enough, Paltrow, the queen ofbizarre beauty treatments(including bee sting treatments and vaginal steaming) confessed that even she hadnt tried leeches yet. Wow! I thought I was batscrazy!, she said.

So whats so special about leeches? Although the Food and Drug Administration approved them as medical devices in 2004, their primary use in medicine has been in reconstructive surgery and microsurgery to help severed veins regain blood flow. Leech therapy has been around for a very long time, but the use of leeches as an anti-aging treatment is a rather recent, celebrity-driven trend (Demi Moore and The Real Housewives of Orange Countys Heather Dubrow are also fans). The idea is that when leeches bite their prey, they feed on the blood while simultaneously injecting numerous substances with a variety of bioactive peptides.

We asked Greenwich, CT, dermatologist Lynne Haven, MD, if leech facials are effective and if they can really make a difference for your skin. According to Dr. Haven, there are far better ways to anti-age than employing the use of blood sucking leeches. Historically, leeches have been used because they have an anticoagulant, so theyve been used for bloodletting, or to increase blood flow to a skin flap or graft, she says. If youre a normal, healthy person there is no medical reason to use a leech. And I think that leech facials dont make any sense.

If youre looking for the best anti-aging treatments, Dr. Haven says youre likely to achieve better results with some tried-and-true skin care services that dont involve slimy, blood sucking creatures: I would not recommend a leech facial, some people can have an allergic reaction to the anticoagulant they produce called hirudin. Theres really no proven benefit and we have so many proven techniques, therapies and topicals with science behind them, that theres really no reason to follow this fad. For overall anti-aging, I would prefer a fractionated laser, topical retinoids, antioxidants and other proven treatments that have been shown to really make a difference in lines and wrinkles.

Original post:
A Top Dermatologist Weighs in on Miranda Kerr's Leech Facial - NewBeauty Magazine (blog)

Chinese Medicine is Using Donkey Skins to Boost Libidoand Africa's Animals Are at Risk – Newsweek

Demand for a form of traditional Chinese medicine is putting the donkey population at risk in South Africa and other parts of the continent.

In recent years, the market in ejiaoa product made from boiled-down donkey skins mixed with herbs and other ingredientshas grown massively in China, putting millions of donkeys at risk of slaughter or poaching.

In South Africa, poor farmers who rely on donkeys as beasts of burden and modes of transport have reported having their animals stolen, only to later find their skinless carcasses.

Subscribe to Newsweek from $1 per week

South Africas Society for the Prevention of Cruelty to Animals has confiscated more than 1,000 donkey hides en route to China in the past year, chief inspect Mpho Mokoena told Voice of America (VOA). Mokoena fears that the growing trade in donkey skins could signal the extinction of the animal in South Africa. In two years there wont be [any] donkeys in South Africa, she told VOA.

Donkey skins dry in the sun at a licensed specialized slaughterhouse in Baringo, Kenya, on February 28. The trade in donkey skins is legal in some countries, but is putting donkey populations in parts of Africa at risk. TONY KARUMBA/AFP/Getty

The slaughter of donkeys and trade in their skins is on an upward trend in other parts of Africa, too. A January report by U.K.-based charity the Donkey Sanctuary found that demand for donkeys in Africa has risen so much that, in the West African country of Burkina Faso, the cost of a single animal almost doubled from 60 ($76) in 2014 to 108 ($137) in 2016.

Read more: Take Two Herbs and Call Me in the Morning

The global donkey population stands at around 44 million, the vast majority of which are working animals, but the Donkey Sanctuary report estimated that global demand for donkey skins is between 4-10 million, with at least 1.8 million donkey skins being traded per year.

Four African countriesBurkina Faso, Mali, Niger and Senegalhave banned donkey exports, as well as Pakistan. The consumption of donkey meat is also considered haram (forbidden) in Islam, meaning that the slaughter of donkeys in many countries with large Muslim populations is frowned upon.

Donkeys are under threat largely due to the rise in popularity of ejiao, according to the report. In China, some believe that ejiao has various health benefits, from anti-aging properties to boosting sex drive, and it is even marketed as a gynecological treatment that can reduce reproductive diseases in women. Demand is so high that ejiao can sell for up to 300 ($382) per kilogram, according to the Donkey Sanctuary report.

Traditional medicine in China and other parts of East Asia is associated with the decline of other animal populations and wildlife agencies have said that wild rhinoceros could be wiped out within a decade as a result of increased poaching. Rhino horn can sell for up to $60,000 per kilogrammore valuable by weight than gold or diamondsdue to myths that it can solve a wide range of medical ailments, including cancer and hangovers.

Tiger bones are also reputed to be a remedy for arthritis in traditional medicine, while ivory from elephant tusks is also used in some medications, as well as being prized for ornamental purposes in China.

Read more:
Chinese Medicine is Using Donkey Skins to Boost Libidoand Africa's Animals Are at Risk - Newsweek

How Pasteur’s Artistic Insight Changed Chemistry – New York Times


New York Times
How Pasteur's Artistic Insight Changed Chemistry
New York Times
In a paper published last month in Nature Chemistry, Dr. Gal explains how a young Pasteur fought against the odds to articulate the existence of chirality, or the way that some molecules exist in mirror-image forms capable of producing very different ...

Here is the original post:
How Pasteur's Artistic Insight Changed Chemistry - New York Times

Biotechnology company opens mosquito factory in Lexington – Lexington Herald Leader


Lexington Herald Leader
Biotechnology company opens mosquito factory in Lexington
Lexington Herald Leader
A Lexington biotechnology company aimed at fighting mosquito-borne diseases such as the Zika virus opened a mosquito factory Friday on Malabu Drive. MosquitoMate, a biotechnology company founded by University of Kentucky entomology professor ...

and more »

Go here to see the original:
Biotechnology company opens mosquito factory in Lexington - Lexington Herald Leader

Genome editing tools set to bring monumental change to healthcare – Healthcare IT News

It may still seem like science fiction, but the ability to nip-and-tuck problematic genomes to cure disease is easier than ever and will soon be getting easier.

At the HIMSS Precision Medicine Summit on Monday, Ross Wilson, principal investigator at UC Berkeley's California Institute for Quantitative Biosciences, explained how tools such as CRISPR-Cas9 are set to transcend the confines of the lab to fundamentally change clinical care.

While there have been some intriguing recent strides made with gene editing technology, Wilson admits that so far, at least CRISPR's "hype eclipses early success stories."

But five to 10 years from now, he said, it "will come into its own and be safe and effective."

The process of fixing certain inheritable diseases by accessing the genome and fixing the root cause is clearly far more complex than the "cut-and-paste" analogies Wilson used to explain advanced precision medicine techniques to non-scientists.

But CRISPR-Cas9 is a "readily programmable genome-editing tool" that makes the process more intuitive and usable for researchers and clinicians than ever before.

[Also:How precision medicine can fix a broken healthcare system]

For an analogy, Wilson likened the use of similar techniques known as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) as wheeling in an '80s-era arcade game to play Frogger or Pac-Man. CRISPR-Cas9, he said, was more akin to an easy and agile Playstation.

That said, the "future of medicine" is still some way off from full fruition. There are three key hurdles to overcome, said Wilson:

Efficacy. Although cutting out a gene can be done reliably, it's still not easy or efficient to "paste" the corrected gene.

Delivery. Researchers still lack robust and reliable technology for sending genome-editing enzymes to the cells in need of repair.

Genetic understanding. Clinicians' ability to cure disease remains hamstrung by an impressive but still too limited knowledge of the underlying genetic causes, said Wilson.

"The total scope of genome editing will be defined by our genetic understanding," he said.

There are currently three conceivable approaches to genome-editing, in order of prevalence, said Wilson: ex vivo, in vivo (systemic), in vivo (targeted).

The "earliest success stories will be ex vivo" enabling clinicians to snip and edit genomes in a petri dish with a "high-efficiency that will let you do the 'pasting' of the effective gene that's hard to do in the host," he said.

In vivo delivery essentially allowing gene editing to be done by injection, whether into the body as a whole or "compartmentalized" to specific places such as the brain or the eye is the "holy grail," said Wilson. The challenge, of course, is that it's hard to distribute effectively to the correct areas of the body.

[Also:Eric Dishman wants precision medicine to move from personal to universal]

Taken as a whole, gene editing has come a long way in recent years. Early trials have been promising for diseases such as cancer, sickle cell anemia and eye disease, he said. Soon after, "I expect to see good progress on" cystic fibrosis, Duchenne muscular dystrophy, Huntington's disease and hemophilia.

Then there are areas where "I think we'll be able to see genome editing applied to things that might be a bit more elective, but could have huge impact, since they're so common," said Wilson, such as Alzheimer's, diabetes, osteoporosis, HIV risk and cholesterol.

Still, he cautioned, "we have to wait a few years to see how safe effective this could be."

One complication for therapeutic genome editing is simply the existence of such a dizzying array of genetic diversity.

Wilson notes that it's "kind of incredible" that, of 3 billion bases in the human genome, just 3 million bases ("a fraction of a percent") of are responsible for all human diversity." Moreover, 100 to 200 bases worth of new changes arise per generation.

That means that close attention must be paid to genetic diversity and novel mutations in order to minimize the serious risks of off-target genomic editing.

Still, Wilson is convinced that genome sequencing will "come to the forefront" of primary care in the near future, with these techniques more commonly identifying genetic risk factors.

That comes with big responsibilities. Clinicians will have to design sequences to minimize off-target risks something that demands whole-genome analysis and "an established gene target will have several validated flavors of enzyme, and the appropriate one will be administered based on the patients genetic profile," he said.

Twitter: @MikeMiliardHITN

Link:
Genome editing tools set to bring monumental change to healthcare - Healthcare IT News

London Theater Review: ‘Anatomy of a Suicide’ – Variety

The sins of the father revisited on the son its a stage staple that tracks back to Ancient Greece. From Captain Alving in Ibsens Ghosts to Arthur Millers arms-dealing Joe Keller in All My Sons, a mans acts live on. Feminist playwright (Revolt. She Said. Revolt Again.) and screenwriter (Lady Macbeth) Alice Birch offers an alternative in this chilly triptych, now play at the Royal Court Theater. Not once, but twice, a mothers trauma rebounds on her daughter. Mental illness becomes a baton passed between three generations: a frazzled 1970s housewife, a 1990s riot girl, a detached doctor in 2033. Katie Mitchells clinical staging forces us to watch forensically, sifting for clues about causality. Is this nature, nurture or social structure?

Birch splits the stage in three, so that three women, decades apart, appear side by side. In 1971, Carol (Hattie Morahan) emerges from hospital with her wrists wrapped in bandages, her husband berating her for ruining the floorboards. In 1997, Anna (Kate OFlynn) wobbles on her feet, off her bloodied head, with one arm in a sling, as a male nurse checks her over and ticks her off. In 2033, a third woman holds her bleeding hand, a fishhook dug into the palm but its her expressionless doctor, Bonnie (Adelle Leonce), who assumes importance.

These women couldnt be more different, and yet their individual stories echo each other sometimes exactly, as phrases and gestures ripple through time. Carol sits at home, alone, infantilized by her stern, shambolic husband (Paul Hilton), smoking at the kitchen table, a child crying somewhere in the house. Anna rampages off the rails, a laddette with a heroin addiction partying through the millennium. Bonnie, meanwhile, shuts everyone out. She might seem the most sorted of the three, but shes not really. All three incur mental health problems of some form or another: a mix of anxiety, depression and detachment.

Its only gradually that we realise that theyre related three generations of the same family. As each individual narrative unfolds, it adds a little more context to the next. One womans life encompasses the others childhood, and so explains the issues they face in adulthood. Eerily, you intuit their deaths before they take place. Each is strangely absent from their daughters life and yet, equally, ever-present.

Its a beautifully organised play, an elegant information overload. Birch is an exacting writer; Revolt. She Said. Revolt Again proved her precision with language, but here, as in her recent film Lady Macbeth, she lets small slices of life assume momentous significance. As Carol smokes a sly cigarette at a childrens party, Anna crashes into a drug-induced coma. Bonnie stands outside a birthday bash, bottle in hand. Many of the micro-scenes have a painterly quality, a stark, unsentimental beauty.

Set designer Alex Eales encases the women in a grey concrete cell so that the world seems oddly absent, and only James Farncombes articulate lighting gives a sense of place. Melanie Wilsons soundscapes swim around like underwater echoes. Between scenes, as the years pass, the women stand, still as mannequins, as castmates undress and reclothe them. Fashions change, women dont, nor society neither any shifts are merely superficial. Birchs play is, among other things, a history of the care system. Patrician doctors become scrubbed-up careworkers, but the treatment prescribed is still the same: electric shock therapy.

As youd expect of the meticulous Mitchell, all three women are played with extraordinary clarity. Morahan wears a faraway frown as Carol, her eyes wide and watery, while OFlynn chews her words as if permanently brain-fuzzed and physically discombobulated. Leonce plays Bonnie with a clean-cut aloofness that almost borders on dissociation, as if to complete the cycle.

Theres something schematic in a play that works entirely through patterns. Birch asks us to compare and contrast, but the triptych form can feel like the complete-the-sequence section of an IQ test: A, B, ?. A mother who feels too little produces a daughter who feels too much. Her daughter, in turn, retreats to a numb silence. Sarah Blenkinsops costumes stress the point: Carol in red, Anna in green and black, Bonnie in white with hints of red. The driving concept is too close to the surface here, the causal chain too certain to ring true. That each woman is so of-their-own-era only exacerbates the problem. All three feel emblematic, rather than idiosyncratic individuals, and it can feel like Birchs thesis is leading her play.

Thats a small grumble, though, in an otherwise unflinching examination of motherhood and mental health, articulated with a sharp sense of theater.

Royal Court Theatre, London; 465 seats; 45, $57 top. Opened, June 8, 2016 reviewed June 8, 2016. Running time:2 HOURS.

A Royal Court production of a play in one act by Alice Birch.

Directed by Katie Mitchell; Set design,Alex Eales; costume design, Sarah Blenkinsop; lighting, James Farncombe; sound, Melanie Wilson; composer, Paul Clark.

Gershwyn Eustache Jnr, Paul Hilton, Peter Hobday, Adelle Leonce, Sarah Malin, Jodie McNee, Hattie Morahan, Kate OFlynn, Sophie Pettit, Vicki Szent-Kirallyi, Dickon Tyrrell.

Read more:
London Theater Review: 'Anatomy of a Suicide' - Variety

OSU baseball: The anatomy of the Beavers’ extraordinary win streaks – Albany Democrat Herald

The two longest winning streaks in Division I baseball this year belong to Oregon State.

The top-seeded Beavers (54-4), who open the College World Series at noon Saturday against Cal State Fullerton (39-22), will take the field at TD Ameritrade Park in Omaha, Nebraska as winners of 21 consecutive games. OSU closed the regular season with 16 straight victories and has outscored opponents 44-9 during its five NCAA tournament games.

Earlier this year, the Beavers won a program-record 23 in a row from Feb. 25 to April 9, including a 12-0 start in Pac-12 play.

The two streaks have accounted for 44 of the teams 54 victories, another single-season school record. With a winning percentage of .931, OSU is on pace to break Arizona States 45-year-old all-time mark of .914 (the Sun Devils finished 64-6 in 1972).

Below is a breakdown of the Beavers winning streaks.

Runs scored: 136 (5.9 per game)

Runs allowed: 49 (2.1 per game)

A loss to Ohio State, which finished 148th in the NCAA RPI, dropped Oregon State to 5-1 early in the season.

The Beavers began the longest winning streak in school history with a 5-2 neutral-site victory over Nebraska, which later came to Oregon for the Corvallis Regional. OSU then got revenge against the Buckeyes to wrap up play in Surprise, Arizona before sweeping consecutive home series with UC Davis and Ball State.

Entering Pac-12 play 14-1 overall, the Beavers outscored Arizona State 16-1 during the three-game set to seize an immediate stranglehold on the conference standings. Starting pitchers Luke Heimlich (eight two-hit innings), Bryce Fehmel (eight innings, one run, four hits) and Jake Thompson (7 two-hit innings) were close to untouchable in the desert.

OSU picked up its first of six walk-off wins at Goss Stadium on March 24, knocking off Arizona 4-3 on a KJ Harrison single that plated Adley Rutschman. The Beavers trailed 3-1 entering the eighth.

One night later, OSU again overcame a deficit and walked off again when Preston Jones scored all the way from second on a wild pitch for a 5-4 win. A comfortable 11-7 decision in the series finale pushed the team to 20-1 overall and 6-0 in Pac-12 play.

The Beavers kept the streak alive with another come-from-behind effort, scoring three times in the ninth to steal a 4-3 victory at Saint Marys on March 28. Nick Madrigal collected the game-winning hit, a two-out, two-RBI single with the bases loaded.

Following another road sweep in which the Beavers outscored Stanford 25-8, OSU pulled out a 4-3 road decision at Portland for its 20th win in a row. Rutschmans two-run single in the sixth put the Beavers in front for good.

A home sweep of Utah including two more walk-offs left OSU 28-1 overall (12-0 Pac-12). Steven Kwan hit a game-winning single in the opener while a Rutschman sacrifice fly brought home Jack Anderson for a 5-4, 16-inning victory in Game 2.

The streak finally came to an end April 13, a 3-2 loss at Washington. But the Beavers fought back to win the final two games of the series.

Runs scored: 158 (7.5 per game)

Runs allowed: 41 (2.0 per game)

After starting the year 28-1, the Beavers went just 5-3 during a two-week span from April 13-29. The rocky patch included a 7-5, 10-inning home loss to USC, which finished in the Pac-12 basement with Arizona State.

Oregon State came back to rout the Trojans 10-1 in the series finale, igniting a winning streak that has yet to end.

A midweek home victory over Oregon followed by a three-game sweep of California put the Beavers on the brink of the Pac-12 championship. After cruising past the Ducks in Game 1 of the Civil War conference series, Mitchell Verburg struck out Ryne Nelson with the bases loaded in the bottom of the ninth to seal a 5-4 victory and the outright Pac-12 title.

Verburgs heroics also delivered career win No. 1,000 for coach Pat Casey.

The Beavers blanked Oregon 1-0 to sweep the series and cruised by Portland two days later before coming out flat against Washington State May 19. Trailing 3-2 entering the ninth, Steven Kwan and Jack Anderson drew consecutive base-loaded walks off Cougars closer Scott Sunitsch for a true walk-off.

OSU went on to outscore Washington State 19-3 in the final two games of the series, finishing with the best record in conference history at 27-3.

The streak nearly ended again May 26 against Abilene Christian, the Beavers final regular-season opponent. Knotted at 4 in the bottom of the 11th, Anderson knocked in Andy Atwood with a single for the teams sixth walk-off of the year. Reliever Mitch Hickey proposed to his girlfriend on the Goss Stadium turf immediately following the game.

The Beavers entered the NCAA tournament with a 49-4 record and breezed through the Corvallis Regional, outscoring Holy Cross and Yale by a combined margin of 27-3. Two comfortable wins over Vanderbilt in the Corvallis Super Regional pushed the winning streak to 21 as OSU prepares for its CWS opener.

Follow this link:
OSU baseball: The anatomy of the Beavers' extraordinary win streaks - Albany Democrat Herald

A Controversial Study Is Tearing the CRISPR World Apart – Gizmodo

When people talk about the gene-editing technology CRISPR, its usually accompanied by adjectives like revolutionary or world-changing. For this reason, its no surprise that a study out last month questioning just how game-changing the technology really is caused quite a stir.

Its well-known that using CRISPR can sometimes also result in some unintended genomic changes, and scientists have long been working on ways to fine-tune it. But the researchers found that when they had used CRISPR to cure blindness in mice, it had resulted in not just a few but more than a thousand, unintendedoff-target effects.

This finding warns that CRISPR technology must be further tailored, particularly before it is used for human gene therapy, the researchers wrote. The technique has already been used in two human trials in China, and next year one is slated to kick off in the US.

Their finding kicked off a battle for CRISPRs honor, with some researchers speaking out to question the studys methods while others piped up to agree that CRISPR is not yet ready for people.

The first criticism came the day after the study was published, via a comment from a researcher on PubMed who argued careless mistakes and flaws in the methodology cast serious doubts about the results or interpretation, concluding that it was hard to imagine CRISPR-cas9 causes so many [unintended] homozygous deletions in two independent mice.

On social media, scientists raised red flags about basic mistakes, such as misidentifying genes, mislabeling genetic defects, and the small number of animals the researchers had included in their research.

I think the Nature Methods paper was a false alarm on CRISPR induced mutations, the geneticist Eric Topol told Gizmodo. Ironically, the methods used were flawed. While we remain aware of such concerns unintended genomic effects that might occur with editingthat report was off-base.

Scientists from the CRISPR-focused companies Intellia Therapeutics and Editas Medicine sent separate letters to the journal, Nature Methods, chiming in with their own critique.

Based on the information available on the mouse study, the more plausible conclusion is that the genetic differences reflect a normal level of variation between individuals in a colony.

We believe that the conclusions drawn from this study are unsubstantiated by the disclosed experiments as they were designed and carried out, the scientists from Editas wrote. Further, it is impossible to ascribe the observed differences in the subject mice to the effects of CRISPR per se. The genetic differences seen in this comparative analysis were likely present prior to editing with CRISPR.

The study sent the stocks of those two companiesand a third, CRISPR Therapeuticstumbling. Nearly two weeks later, those market prices had still not fully recovered. Some went so far as to call for a retraction.

All of our methods are described in our peer reviewed Correspondence and sopplemental materials in Nature Methods and the raw data have all been publicly deposited, so that others may further learn from our data, one of the authors, Alexander Bassuk, told Gizmodo via email.

Springer Nature, which owns Nature Methods, said that they have received a number of communications regarding the paper and said that it had undergone peer review as all papers in the journal do.

We are carefully considering all concerns that have been raised with us and are discussing them with the authors, a spokesperson said.

On his blog, UC Davis professor Paul Knoepfler asked several scientists about the study and got mixed results. One cited the same flaws in methodology others have brought us. Another posited that it was a good reminder to hunt thoroughly for off-target effects.

Overall, this study adds a bit to the knowledge base, but it has been over-interpreted in the media, Knoepfler concluded. It was unlikely, he wrote, that so many unintended edits were occurring in most research, but it still suggested more studies to investigate the problem are necessary.

This brings us to the one thing that is definitely true: Despite all our recent progress, there is still a lot we dont know about CRISPR. It does indeed allow us to make precise gene edits more easily than ever before, but this ability has limitations that could wind up being disastrous if used in humans, and disappointing when genetically engineering everything else. CRISPR is still a nascent technology, and whether one day it might really be used to cure diseases or create a unicorn, there are still a whole lot of things that need to happen first.

Update: This story has been updated to include comments from one of the study authors, Nature Methods and Eric Topol.

More here:
A Controversial Study Is Tearing the CRISPR World Apart - Gizmodo

Scientist John Shine honoured for discovery that formed basis of genetic engineering – The Guardian

Prof John Shine in 2015. Shine discovering a sequence of DNA now called the Shine-Dalgarno sequence which allows cells to produce proteins the basis for how all our cells operate. Photograph: Mal Fairclough/AAP

A man whose discovery was essential for the development of genetic engineering, and used that technology to create several therapies now helping many thousands of people, says receiving a Queens Birthday honour is a great recognition from the community of the value of scientific research.

John Shine started his career by discovering a sequence of DNA now called the Shine-Dalgarno sequence as part of his PhD in the mid 1970s.

That sequence, while a minuscule part of the human genome, allows cells to produce proteins the basis for how all our cells operate.

The discovery was essential for genetic engineering, spawned an entire biotech industry, and has now been used to produce therapies that have helped millions of people. In his own work, Shine used those techniques to clone of human insulin and growth hormone for the first time.

Other scientists honoured on Monday included astronomer Ken Freeman, who founded the field of galactic archaeology, and ethnobotanist Beth Gott.

Shine, who was appointed a Companion of the Order of Australia today, told the Guardian he has been unusually lucky in his career to have been able to oversee discoveries he made in basic sciences, be translated into real therapies and become commercialised.

My PhD was really esoteric research, he said, referring to his discovery of the Shine-Dalgarno sequence . But then I went over to San Francisco when gene cloning was just beginning right place, right time.

Shine had discovered how to clone the human gene that produces insulin, but to make that useful, it needed to be inserted into another organism that could be farmed in this case, bacteria, which would be farmed in large vats.

But if you want to put [the gene] into bacteria to make human insulin, you needed to trick the bacteria into thinking the gene was one of its own, he said.

It turned out Shines earlier discovery of the Shine-Dalgarno sequence was essential for making that final leap. Although the genetic code is the same in animals and bacteria, the regulatory code was very different. Thats where the Shine-Dalgarno sequence comes in, Shine said.

He needed to find the bacterias version of the Shine-Dalgarno sequence, and put that on either side of the human insulin gene, inside the bacteria.

You needed to put the right Shine-Dalgarno sequence just in front in the right place in the insulin gene to make the bacteria produce human insulin.

The fact that both problems were so closely related was mostly an accident, Shine says.

But throughout the rest of his career, Shine continued to be involved in the translation of his discoveries in esoteric science, all the way through to commercialisation.

Since stepping down as the head of the Garvan Institute in 2011 one of Australias top medical research institutes Shine has been the chair of the biotech giant CSL, one of Australasias largest companies.

So Ive come full circle, Shine said. CSL ... in more recent years, were moving into genetic engineering and weve released several genetically modified proteins for haemophilia that are changing the lives of thousands of people around the world.

Ive been very lucky to be able to go through the basic research in my career, and now see a lot of these real health care products come to fruition and improve the lives of thousands of people. Its wonderful when you can have all the excitement of research but also the satisfaction of seeing something very good coming out of it.

It is not the first time Shine has been recognised publicly for his work. In 2010 he won the prime ministers prize for science something his brother Rick Shine won in 2016.

Apart from the obvious personal honour, its a demonstration that the community does appreciate the benefits that come from research, Shine said. The wellbeing of any society is intimately linked to good healthcare.

Another winner of the prime ministers science prize, astronomer Ken Freeman, was appointed a Companion of the Order of Australia for his founding contributions to the field of galactic archaeology and his teaching work at the Australian National Universitys Mount Stromlo Observatory.

Honours were also awarded to Royal Melbourne hospitals Peter Grahame Colman (AM), for his work in endocrinology and diabetes research; aeronautical engineer Graeme Bird (AO), the former department head at the University of Sydney and a NASA consultant for 40 years; and Peter Klinken (AC), the chief scientist of Western Australia.

Ethnobotanist Beth Gott was made a Member of the Order of Australia for her work studying native plants and their use by Indigenous people. Gott founded Monash Universitys Aboriginal education garden in 1986 and has assembled databases of native plants in south-eastern Australia.

A paper she wrote in 2005 for the Journal of Biogreography found Indigenous fire-farming was crucial to the growth of plant tubers in southeastern Australia, allowing them to make up half of the local peoples diet.

See the original post:
Scientist John Shine honoured for discovery that formed basis of genetic engineering - The Guardian

NIAID scientists discover rare genetic susceptibility to common cold – National Institutes of Health (press release)


National Institutes of Health (press release)
NIAID scientists discover rare genetic susceptibility to common cold
National Institutes of Health (press release)
The case, published online today in the Journal of Experimental Medicine, reveals an important mechanism by which the immune system responds to these viruses, say the study authors. Several weeks after birth, the child began experiencing life ...

and more »

Original post:
NIAID scientists discover rare genetic susceptibility to common cold - National Institutes of Health (press release)

Why doctors’ offices could become obsolete – San Francisco Chronicle

A man showing early signs of a heart attack detected by a bot tracking his heart activity from a sensor on his wrist is picked up by a self-driving car that checks his vital signs on the way to the hospital. There, his doctors video-conference with a specialist, who assesses his symptoms through a Skype-like screen and recommends a treatment plan.

The scenario, inconceivable a generation ago, is closer than you might think. Technological advancements are ushering in a new era of health care, eroding the long-held model of hospitals and doctors offices as the physical center of the health system. The change is unfolding on many fronts, and experts say we are on the cusp of a revolution that could come within the next decade.

The growth of telemedicine (video chats with your doctor) and tools to track chronic diseases (wearable glucose-monitoring devices for diabetics) is inching us toward a time when medical care and diagnoses can be accessed from afar, and often without having to see a physician in person.

The explosion of relatively inexpensive direct-to-consumer genetic tests is allowing millions of people to learn potentially life-changing medical information about themselves without ever stepping foot in a doctors office.

And cutting-edge research in gene therapy is opening the door to the possibility of people with genetic diseases being treated much earlier in life, and being cured for longer periods of time potentially improving the quality of life for millions.

This rapidly changing landscape raises the question: Will there come a day when we wont need to go to the doctors office anymore? Will we be able to navigate the health system without coming into contact with a medical professional? And would that be good or bad?

Unit coordinator Ricky Ng does prep work for recently admitted patients and supports patient information for critical care nurses at California Pacific Medical Center's eICU hub.

Unit coordinator Ricky Ng does prep work for recently admitted...

Developers of self-driving cars are already considering including some basic inward-facing sensors that can be used for medical applications such as those that can measure temperature or cameras that can visually assess the health of a passenger to aid the elderly and people with disabilities, according to Nidhi Kalra, senior information scientist at the think tank Rand Corp. who researches autonomous car policy.

Unit coordinator Ricky Ng (left) talks with critical care nurse Clark Wurth at California Pacific Medical Centers eICU hub, where off-site ICU patients are monitored on computers.

Unit coordinator Ricky Ng (left) talks with critical care nurse...

Some people may have health complaints or challenges that the car needs to be aware of as its taking them to the mall, she said.

Kaiser Permanente, one of the largest health systems in Northern California, recently set up a futuristic mock exam room where patients can sit in front of a computer screen to talk to a doctor remotely while using a stethoscope, digital thermometer and otoscope to check their own symptoms under the guidance of the physician. Kaiser CEO Bernard Tyson has personally participated in the experiment.

That is the future being able to provide a great health care service without someone having to get up and go all the way across town for that kind of medical visit, Tyson said. All these things represent the moving away from the hospital being the centerpiece of health care.

Critical care nurse Karen Laberge monitors vitals of present ICU patients at California Pacific Medical Center's eICU hub.

Critical care nurse Karen Laberge monitors vitals of present ICU...

Last year, 70 million interactions between Kaiser patients and their primary care doctor were done by secure email, video conference and other remote tools.

Worldwide revenue for telehealth devices and services is expected to hit $4.5 billion next year, compared to $441 million in 2013, according to the business analytics firm IHS Technology. During the same period, the number of people using telehealth services each year is projected to grow from 350,000 to 7 million.

I dont think well get to a point where well never see a doctor, but a large percentage (of doctors) will be seeing patients remotely in the future, said Dr. David Tong, director of the telestroke program at California Pacific Medical Center in San Francisco. His program connects his vascular neurology practice with 20 other hospitals from the Oregon border to Visalia, so hospital physicians can seek his help in treating a stroke patient. Tong does a visual assessment of the patients using technology similar to Skype.

Tong has led the program since its inception a decade ago, when just two hospitals were in the telestroke network, and the concept of talking to a doctor through a screen seemed foreign to many patients. Today, its commonplace People think, If I do this all the time with my friends, Ill do it with my doctors too. Whats the difference? Tong said.

Despite the promise of remote medical care, though, many traditional barriers to health care remain. Wealth, geography and access to insurance are privileges that no app or technological advancement can replace.

The major stumbling block right now is financial, said Tong. Right now, most insurance doesnt pay for telemedicine in a very efficient way. That blocks some people from doing it.

Medicare and Medi-Cal, for example, limit their reimbursement for telemedicine services to psychiatry and to patients who live in rural areas, Tong said.

There may also be drawbacks to receiving care remotely, which reduces the need for physical interaction. Studies have shown that human touch reduces stress, helps premature babies grow faster and improves the lives of nursing home residents.

A patient's chest x-rays shown on a monitor at California Pacific Medical Center's eICU hub.

A patient's chest x-rays shown on a monitor at California Pacific...

But in another promising development, medicine is also moving in the direction of preventing diseases before they even cause any symptoms. Efforts by genetic testing firms to screen large populations coupled with research in gene therapy and gene editing will give people more information than ever before on their genetic makeup.

As soon as five years from now, everyone who wants to be sequenced will have been sequenced, said Dr. Jill Hagenkord, chief medical officer at Color Genomics, a Burlingame company that sells a $249 test that analyzes 30 genes associated with common hereditary cancers including breast, ovarian and pancreatic cancer. People can buy the test directly from Color or on Amazon, but they must submit their health information and have a physician review it and order the test before Color will analyze the sample.

Whether thats newborn screening in the hospital system or in a research setting ... sequencing data will just exist, Hagenkord said.

Color is already taking steps toward population screening, working with 40 large self-insured employers including Visa and Salesforce which collectively cover tens of thousands of people that subsidize or pay for the test for employees and spouses.

Using gene testing as a preventive tool doesnt take the medical professional out of the equation, but maybe youll just have a conversation earlier with your doctor, about getting a colonoscopy sooner or making choices that may reduce your risk of certain cancers, Hagenkord said.

Meanwhile, researchers are working to bring gene therapy from the clinical trial stage to the real world to treat retinal disease and hemophilia though treatments are not yet available commercially, said Dr. Chris Haskell, who leads Bayer Corp.s West Coast Innovation Center. Bayer has a joint venture with CRISPR Therapeutics which uses the gene-editing tool known as CRISPR to develop and market therapeutics for blood disorders, blindness and congenital heart disease.

With gene therapies, the industry is moving ahead very rapidly in clinical development toward bringing these to patients very soon, Haskell said. Gene editing is still a number of years away behind gene therapy, but has promise for being able to treat many more diseases.

Gene editing is considered a subset of gene therapy. Gene therapy consists of adding a missing part of a persons DNA, typically through an injection of an engineered virus that carries the replacement gene. With the blood-clotting disorder hemophilia A, patients are missing a blood-clotting protein called factor VIII. This protein is injected and, over the course of the next several days or weeks, the cells start producing the clotting factor and allow the circulatory system to clot normally.

The trailblazing is happening with hemophilia because we understand the disease, Haskell said. But theres a huge promise for bringing therapies to patients around the world, especially kids with metabolic disorders who have no good therapy.

Gene editing makes it possible to modify the genetic code and the applications seem limitless.

This opens up a whole new realm of ways to treat diseases in that we can turn things on and off, take things out, Haskell said. With gene therapy, we have the hammer. Now we have the whole toolbox. However, were still learning how to use all these tools.

And the workshop for those tools? It will be anywhere but your old, familiar doctors office.

Catherine Ho is a San Francisco Chronicle staff writer. Email: cho@sfchronicle.com Twitter: @Cat__Ho

Read more:
Why doctors' offices could become obsolete - San Francisco Chronicle

Is CRISPR Gene Editing Moving Ahead Too Quickly? – Healthline

Researchers say they discovered hundreds of mutations during a gene editing experiment, casting doubt on CRISPR's safety and precision.

CRISPR gene editing technology has tantalized the public with its potential to cure disease.

However, new research suggests it could be more dangerous and less precise than previously believed.

CRISPR-Cas9 was discovered in 2012 by University of California molecular biologist Jennifer Doudna and her colleagues. It allows for genetic editing by snipping out small bits of defective or harmful DNA and replacing it.

Gene editing has existed since the 1970s, but CRISPR-Cas9 has reinvented it as a precise, accessible technology.

The potential applications seem almost limitless.

This year, Dr. Edze Westra of the University of Exeter, told the Independent that he expects the technology to be used to cure all inherited diseases, to cure cancers, to restore sight to people by transplanting genes.

Read more: Scientists find gene editing with CRISPR hard to resist

Still in its infancy, CRISPR-Cas9 has yet to deliver on these promises, in humans anyway.

One of the key talking points of CRISPR-Cas9 has been its precision its ability to accurately edit small sections of DNA without affecting nearby sections.

However, a new study from Columbia University says that CRISPR-Cas9 can introduce hundreds of unexpected mutations into the genome beyond what was intended.

We feel its critical that the scientific community consider the potential hazards of all off-target mutations caused by CRISPR, said co-author Dr. Stephen Tsang, a professor at Columbia University Medical Center, in a press release.

Tsang and his team discovered the mutations while conducting research on mice, using CRISPR-Cas9 to correct a gene that caused blindness.

The technology worked effectively in curing the blindness, but when the researchers later looked at the genome of the mice, they said they found additional, unintended mutations.

Despite this, the mice appeared to be in fine health.

We did not see any observable complications in the mice, despite having all these extra CRISPR-related mutations, Tsang told Healthline.

Sheila Jasanoff, professor of science and technology studies at Harvard University, told Healthline that precision can have a slippery definition in biotechnology.

Genetic engineering was also sold some 40 years ago as a highly precise technique. Now, CRISPR is being heralded as even more precise, she said.

Undoubtedly, there is some truth in that claim ... But we also know from older genetic engineering techniques that very precise interventions into one part of a genome can produce unexpected side effects or off-target impacts that scientists were not expecting, Jasanoff added.

Read more: CRISPR gene editing and cancer treatment

Tsang frames the message of his research in two ways.

First, he hopes that his work will bring a newfound awareness to the potential side effects caused by CRISPR.

Although the mutations he and his team observed did not appear to have any malignant effects, they should be a wake-up call for researchers.

Secondly, Tsang says that no matter what kind of medicine or treatment is being used, there is the potential for side effects.

If we apply CRISPR, its just like any other intervention medicine. There is always off-targeting and risks and benefits, he says.

Jasanoff is more tempered in her assessment of the risk vs. reward of CRISPR.

The assumption that there are untold benefits in store long before the work has been done to establish how a new technology actually will have an impact on any disease is a typical example of the hype that surrounds new and emerging technologies, she said.

Tsangs research offers no hard answers to the larger questions of efficacy, risk, and benefit of using CRISPR on humans.

Lets not go overboard, said Pete Shanks, a consultant who is an expert on genetics. Three blind mice dont prove much.

Tsangs research does provide some cautionary insight into how research must be conducted in order to make the technology safer.

Currently most studies of off-target mutations depend on computer algorithms to locate and examine affected areas. Tsang and his team say that this isnt sufficient when using live specimens.

These predictive algorithms seem to do a good job when CRISPR is performed in cells or tissues in a dish, but whole genome sequencing has not been employed to look for all off-target effects in living animals, Alexander Bassuk, professor of pediatrics at the University of Iowa, and co-author of the study, said in a press release.

Researchers who arent using whole genome sequencing to find off-target effects may be missing potentially important mutations, Tsang said.

Read more: Gene editing could be used to battle mosquito-borne disease

This study comes at an important time.

China has begun its first round of human testing using CRISPR-Cas9.

The United States is due to start its own tests next year.

The research field is moving quickly perhaps too quickly.

We hope our findings will encourage others to use whole genome sequencing as a method to determine all the off-target effects of their CRISPR techniques and study different versions for the safest, most accurate editing, Tsang said.

Jasanoff is much blunter.

We should put aside the notion the benefits of CRISPR are already proven, and all we need to worry about is risks, she said.

Visit link:
Is CRISPR Gene Editing Moving Ahead Too Quickly? - Healthline

Genetic engineering boosts immunity against crop disease – Daily Nation

= By ANGELA OKETCH More by this Author 24minutesago

The chemicals that farmers spray on their crops in form of pesticides to kill pests and prevent diseases have always been a bone of contention, with researchers trying to find safer alternatives. A new variety of rice that fights multiple pathogens with no effect on the yield of the crop, is thus a welcome relief for both farmers and scientists.

The discovery is based on a study of the plants immune system. Plants use receptors on the outside of their cells to identify molecules that signal a microbial invasion, and respond by releasing antimicrobial compounds. Therefore, identifying genes that kickstart this immune response yields disease-resistant plants.

Just like sick humans who are unproductive at work, plants grow poorly and produce unfavourable yields when their immune systems are overloaded. For a long time, scientists have focused on the NPR1 gene from a small, woody plant called Arabidopsis thaliana, to boost the immune systems of rice, wheat, tomatoes and apples.

However, NPR1 is not very useful for agriculture because it has negative effects on plants. To make it useful, researchers needed a better gene that would activate the immune response only when the plant is under attack. Rice with the gene was able to combat rice blast which often causes an estimated 30 per cent loss of rice crop worldwide, every year.

A segment of DNA called the TBF1 cassette acted as a control switch for the plants immune response. When the TBF1 cassette from the Arabidopsis genome was copied and pasted alongside and in front of the NPR1 gene in rice plants, it resulted in a strain of rice that could fend off offending pathogens without causing stunted growth seen in previously engineered crops.

The researchers tested the superiority of engineered rice over regular rice by inoculating crop leaves with the bacterial pathogens that cause rice blight and leaf streak, as well as the fungus responsible for blast disease. Whereas the infections spread on the leaves of wild rice plants, the engineered plants confined the invaders to a small area.

The researchers say this innovation could come in handy in the developing world where farmers with no access to fungicide often lose their entire crop to disease. The study was published in Nature.

open close

Read more here:
Genetic engineering boosts immunity against crop disease - Daily Nation